ストックスクリーナーアプリを入手
85.60
1.11%
-0.96
アフターアワーズ：
85.55
-0.05
-0.06%
前日終値:
$86.56
開ける：
$86.39
24時間の取引高:
1.52M
Relative Volume:
0.86
時価総額：
$16.72B
収益：
$4.58B
当期純損益:
$870.87M
株価収益率:
19.45
EPS:
4.4
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
-0.44%
1か月 パフォーマンス:
+9.20%
6か月 パフォーマンス:
+20.92%
1年 パフォーマンス:
+37.49%
1日の値動き範囲:
$85.32
$87.35
1週間の範囲:
$85.06
$87.99
52週間の値動き範囲:
$53.56
$87.99
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
85.60 | 16.90B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Chronic Hand Eczema Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeut - Barchart.com
Incyte (INCY) Rating Affirmed with Increased Price Target by B o - GuruFocus
Can trapped investors hope for a rebound in Incyte CorporationTrade Ideas & Technical Pattern Based Signals - Newser
Is Incyte Corporation forming a bullish divergence2025 Momentum Check & Capital Protection Trade Alerts - خودرو بانک
Incyte’s Pipeline And Profits Shine Despite Patent Uncertainty - Finimize
Does Incyte Corporation stock benefit from AI growthTrade Ideas & Weekly High Potential Stock Alerts - خودرو بانک
Will Incyte Corporation outperform the market2025 Price Targets & Weekly Stock Breakout Alerts - Newser
Technical signs of recovery in Incyte Corporation2025 Trade Ideas & Verified Short-Term Plans - Newser
Using economic indicators to assess Incyte Corporation potentialQuarterly Earnings Summary & Low Risk Entry Point Guides - Newser
Is Incyte Corporation stock reversal real or fake2025 Winners & Losers & Long-Term Growth Plans - Newser
Is Incyte Corporation showing insider buyingDividend Hike & Consistent Income Trade Recommendations - خودرو بانک
Incyte Corp EVP Sheila Denton Buys, Sells Shares on 2025-09-02 - AInvest
Incyte at Wells Fargo Conference: Strategic Growth Plans - Investing.com
What indicators show strength in Incyte CorporationJuly 2025 Technicals & Daily Entry Point Alerts - Newser
Using portfolio simulators with Incyte Corporation includedMarket Activity Recap & Long-Term Growth Portfolio Plans - Newser
Myelofibrosis Market is Going to Grow at a CAGR of 9% in the Next Ten Years (2025-2034) | DelveInsight - sg.finance.yahoo.com
How to build a custom watchlist for Incyte CorporationLong Setup & Expert Approved Momentum Trade Ideas - Newser
Combining price and volume data for Incyte CorporationRecession Risk & Accurate Buy Signal Notifications - Newser
Incyte at Cantor Global Healthcare Conference: Strategic Growth Beyond 2029 - Investing.com
Incyte launches educational campaign to raise awareness of HS - Investing.com
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa - Financial Times
Should you wait for a breakout in Incyte CorporationShare Buyback & Scalable Portfolio Growth Ideas - Newser
Should I invest in Incyte Corporation before earnings2025 Historical Comparison & High Return Stock Watch Alerts - خودرو بانک
Quantitative breakdown of Incyte Corporation recent moveTreasury Yields & Daily Chart Pattern Signal Reports - Newser
What candlestick patterns are forming on Incyte CorporationWeekly Trend Recap & Step-by-Step Swing Trade Plans - Newser
What Fibonacci levels say about Incyte Corporation rebound2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Will breakout in Incyte Corporation lead to full recoveryCPI Data & Proven Capital Preservation Methods - Newser
Cholangiocarcinoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Incyte (INCY) Stock Is Up, What You Need To Know - Yahoo Finance
Advanced analytics toolkit walkthrough for Incyte CorporationJuly 2025 WrapUp & Verified Chart Pattern Signals - Newser
Applying Elliott Wave Theory to Incyte CorporationAnalyst Upgrade & Smart Allocation Stock Tips - Newser
Incyte Corporation stock hits 52-week high at 87.27 USD - Investing.com
What’s the recovery path for long term holders of Incyte CorporationJuly 2025 Opening Moves & Technical Pattern Alert System - Newser
Reversal indicators forming on Incyte Corporation stockWeekly Market Outlook & Intraday High Probability Setup Alerts - Newser
Can Incyte Corporation disrupt its industry2025 Short Interest & Safe Capital Growth Tips - khodrobank.com
What institutional flow reveals about Incyte CorporationJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
How sentiment analysis helps forecast Incyte CorporationBull Run & Fast Exit/Entry Strategy Plans - Newser
Long term hold vs stop loss in Incyte CorporationJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
Will Incyte Corporation stock recover after recent dropDividend Hike & Growth Oriented Trading Recommendations - Newser
Did Incyte's (INCY) Leadership Shift and Pipeline Milestones Just Reshape Its Investment Narrative? - Yahoo Finance
Can technical indicators confirm Incyte Corporation’s reversalPortfolio Risk Summary & Expert Curated Trade Setup Alerts - Newser
How institutional ownership impacts Incyte Corporation stockJuly 2025 Chart Watch & Advanced Technical Analysis Signals - Newser
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
1.96%
0.56%
大文字化:
|
ボリューム (24 時間):